Toggle Mobile Menu

Explore our impact areas and learn about our grantees.

Updates

Medical Research & Talent|October 15, 2021

Clinician-scientist Kipp Weiskopf appointed as a Valhalla Fellow at Whitehead Institute

Kipp Weiskopf—who is identifying ways to prompt macrophages to fight cancer—has been named a Valhalla Fellow.

Medical Research & Talent|September 2, 2021

Two Whitehead Fellows named to MIT and Harvard faculties

Kristin Knouse joined the Massachusetts Institute of Technology (MIT) faculty as an assistant professor of biology and a member of MIT’s Koch Institute for Integrative Cancer. As a Scott Cook and Signe Ostby Fellow at the Whitehead Institute since 2018, Knouse worked to understand how tissues sense and respond to damage.

Medical Research & Talent|June 15, 2021

What We Learned Doing Fast Grants

The founders of Fast Grants share insights from developing and operating a rapid funding platform for COVID-19 scientific research.

Medical Research & Talent|June 3, 2021

The Disease Detective

Dr. Joe DeRisi, a UCSF Sandler Fellow alumnus, invented a way to find pathogens that scientists didn't even know to look for. Can it help prevent the next pandemic?

Medical Research & Talent|April 28, 2021

Smart cell therapies for solid cancers ready to move toward clinical trials

Researchers at UCSF have demonstrated how to engineer smart immune cells that are effective against solid tumors, opening the door to treating a variety of cancers that have long been untouchable with immunotherapies.

Medical Research & Talent|November 20, 2020

New Whitehead Fellow seeks to harness the immune system to fight pancreatic cancer

At Whitehead Institute, Tobi Oni will focus on uncovering mechanisms for the poor anti-tumor immune response to pancreatic cancer, and work to develop novel ways of promoting tumor clearance by immune cells. And—following in his mother’s footsteps—he will pursue opportunities to inspire and mentor the next generation of scientists from diverse backgrounds.

Medical Research & Talent|March 28, 2017

F.D.A. approves new drug to treat severe multiple sclerosis

The drug, ocrelizumab, is one of three new "B-cell" therapies to treat MS that have proven to be extremely effective in preventing MS relapses.